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1. INTRODUCTION 
The resistance of tumor mitochondria to delete- 
rious effects of Ca*+ is firmly established [ 1,2] (re- 
viewed in [31]) but remains largely unexplained. 
Local anesthetics such as nupercaine inhibit mito- 
chondrial phospholipase A2 [4] and stabilize liver 
and heart mitochondria so as to facilitate their ac- 
cumulation and retention of Ca2+ [5-71. These 
agents are also purported to inhibit a specific path- 
way of Ca2+ efflux in liver mitochondria [8,9]. This 
pathway could participate in Ca2+ cycling and its 
uncou ling action. Here, the effects of nupercaine 
on Ca P+ uptake and release by rat liver and Ehrlich 
ascites cell mitochondria have been compared. The 
objective was to probe for possible differences in 
phospholipase A2 activity and Ca*+ efflux in tumor 
mitochondria to explain how they are able to escape 
damage by Ca2+ [lo]. 
The maximum mitochondrial Ca2+ uptake, 
which is a convenient quantitative measure of their 
resistance to damage [lo], is increased 2.5-fold by 
nupercaine in rat liver. The local anesthetic does not 
affect Ca2+ uptake by isolated tumor mitochondria 
or those within digitonin-treated Ehrlich ascites 
cells. Tumor mitochondrial phospholipase A2 may 
therefore be absent or altered. Ntrpercaine-sensitive 
Ca2+ efflux from Ehrlich cell mitochondria can be 
demonstrated but only under selected experimental 
conditions. Attenuation of these nupercaine sensi- 
tive processes can provide an explanation for the 
resistance of tumor mitochondria to damage by 
Ca2+ due to decreased phospholipase activation 
and Ca2+ cycling. 
Nupercaine Ehrlich cells 
2. MATERIALS AND METHODS 
Rat liver mitochondria were isolated from male 
Wistar rats by a modification of the method in [ 111. 
Ehrlich ascites cells were harvested and washed [ 121 
and mitochondria isolated as in [lo]. 
Calcium fluxes were measured spectrophoto- 
metrically with murexide [ 131 or arsenazo III [ 141 by 
means of an Aminco DW-2 dual wavelength spec- 
trophotometer. Other details of the conditions are 
provided in the legends. Protein was assayed as in 
[ 151 with bovine serum albumin as standard. 
All chemicals were obtained from Sigma Chem- 
ical Co. or Fisher Scientific (St Louis MO). Ruthen- 
ium red was recrystallized as in [ 161 and concen- 
trations determined spectrophotometrically [ 161. 
Nupercaine was kindly provided by Ciba Pharma- 
ceutical Co. (Summit NJ) and FCCP was a gift of 
Dr P.G. Heytler, E.I. DuPont de Nemours and Co. 
(Wilmington DE). 
3. RESULTS 
Exogenous Mg2+ enhances maximum Ca2+ 
accumulation by liver mitochondria by -2-fold 
(table 1). Similarly, nupercaine stimulates - 2.5- 
times. The stimulation by Mg2+ is largely sup- 
planted by exposing liver mitochondria to nuper- 
Caine. These results are similar to those in [6] for 
Ca2+ retention by liver mitochondria. The salutory 
influence of adenine nucleotides however is not 
affected by nupercaine. ATP (or ADP; not shown) 
enhances Ca2+ uptake by 1.5-fold with or without 
the local anesthetic (table 1). 
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Table 1 Table 2 
Maximum Ca*+ uptake by rat liver mitochondria Effect of nupercaine on the maximum Ca2+ uptake by 
isolated tumor mitochondria 
Addition(s) 
Ca2+ uptake (pequiv./mg protein) 
- Nupercaine + Nupercaine 
Addition(s) 
Ca2+ uptake (pequiv./mg protein) 
- Nupercaine + Nupercaine 
None 0.68 1.69 
Mg2 + 1.25 1.86 
Mg* + , ATP 1.67 2.42 
None 1.88 1.86 
Mg2+ 2.86 2.87 
MS*‘, ATP 3.66 3.70 
The reaction medium consisted of 250 mM sucrose, 5 
mM Tri-succinate, 2.5 mM Tris-Pi, 20 mM Tris-HCl 
(pH 7.2), BSA (1 mg/ml) plus 60 PM murexide. Mito- 
chondria were pretreated with rotenone (0.4 pg/mg) and 
added at -0.35 mg/ml and preincubated 1 min before 
Ca*+ additions (100 PM each). The reaction mixtures 
were aerated for 5 s every 2-3 cycles of Ca2+ uptake. 
When included, nupercaine (250 PM), MgC12 (2 mM), 
and ATP (1 mM) were added initially as indicated. The 
values are means derived from at least 4 separate xperi- 
The reaction medium, conditions of Ca*+ loading and 
concentrations of added substances were identical to 
those in table 1. The final concentration of tumor mito- 
chondria was -0.3 mg/ml and oligomycin (1.2 pg/ml) 
was included. The values are means for three or more 
separate preparations 
ments 
nupercaine. The insensitivity of Ca2+ accumula- 
tion to nupercaine is also demonstrable with tumor 
mitochondria in situ; i.e., within digitonin treated 
Ehrlich cells [lo]. 
Unlike liver mitochondria, nupercaine has little 
effect on the maximum Ca2+ uptake of isolated 
tumor cell mitochondria (table 2). Stimulation by 
M&J+ and ATP is observed as in liver; however, 
both are the same in the presence or absence of 
Mitochondrial Ca2+ uptake by digitonized cells 
(table 3) is stimulated only 12% at the optimum 
concentration of nupercaine (250 PM). Exogenous 
Mg 2+ does not stimulate which is attributed to re- 
tention of Mg2+ by digitonized cells [lo]. These 
Table 3 
Influence of nupercaine on the maximum Ca2+ uptake by mitochondria of digito- 
nin-treated Ehrlich ascites cells 
Addition(s) Ca*+ uptake 
(pequiv./ lo8 cells) 
Mitochondrial Ca2+ 
uptake (nequiv./ 
mg protein) calc.a 
None 
Nupercaine 
125 PM 
250 ,uM 
500 PM 
Mg2+, 2 mM 
Nupercaine, 250 PM 
+Mg2+,2mM 
5.94 2.70 
5.20 2.36 
6.68 3.04 
6.38 2.90 
5.97 2.71 
5.89 2.68 
a Calculated for a mitrochondrial content of 2.2 mg protein/ 10s cells [lo] 
The reaction conditions were the same as in tables 1 and 2 except Ehrlich cells (at 
final cont. -5.5 x 106/ml) were treated with digitonin (350 pg/ml) and oligomycin 
(3.0 pg/ml) in addition to rotenone (present at 1.6 pg/ml). The values are means 
from results with three different cell preparations 
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A 
Ca++ Load (neqlmg protein) Ca++ Load (neqlmg protein) 
Fig.l(A,B). Nupercaine sensitivity of Ca2+ release from tumor mitochondria. The reaction medium was as in table 1 
except arsenazo III (10 PM) was substituted for murexide. Mitochondria (pre-treated with rotenone and oli omycin, 0.4 
,t@mg and 2.0 ).@mg, respectively) were at %+ as in the - 0.3 mg/ml and preloaded with the indicated quantities of Ca 
previous experiments. After achieving a steady state, Ca 2+ efflux was initiated with ruthenium red (0.8 nmol/mg) in the 
presence and absence of nupercaine (250 PM) added 10 s before ruthenium red (A). When included, FCCP (2 PM) was 
added immediately after ruthenium red (B). The results are representative of 3 separate experiments (solid lines and 
symbols, with nupercaine). 
observations indicate Ehrlich cell mitochondria are 
not altered during isolation to explain their in- 
sensitivity to nupercaine. Nupercaine was tested 
next for effects on Ca* + efflux. 
Steady state Ca*+ release caused by inhibiting 
uptake with ruthenium red has been ascribed to a 
specific efflux pathway inhibited by local anesthetics 
[8,9]. Nupercaine did not inhibit ruthenium red- 
dependent Ca*+ efflux from tumor mitochondria 
(fig.lA). Nupercaine stimulated slightly presum- 
ably due to a slight uncouplin 
ruthenium red-dependent 
gj :ff;z;eI,“,““; 
Ca 
with uncoupling agent [17] is inhibited by nuper- 
Caine (fig.lB). The extent of inhibition ranges 
from 40-60% depending upon the Ca*+ load. This 
differential sensitivity to nupercaine implies the 
existence of 2 efflux pathways. Results obtained 
with rat liver mitochondria under comparable con- 
ditions are dealt with below. 
4. DISCUSSION 
The maximum Ca*+ uptake of tumor mitochon- 
dria is 2-3-times that of liver mitochondria depend- 
ing upon whether they are supplemented with 
exogenous Mg*+ and Mg*+ plus ATP. Liver mito- 
chondria treated with nupercaine take up the same 
amount of Ca*+ as tumor mitochondria (1.69 
and 1.86 pequiv. Ca*+ /mg protein, respectively) or 
-70% in the presence of Mg*+ with and without 
ATP. The close agreement between values (espec- 
ially without Mg*+ and adenine nucleotide) could 
be fortuitous or correspond to the Ca*+ uptake 
capacity of mitochondria when phospholipase A2 
activity is minimal; i.e., inhibited by local anesthetic 
in rat liver 15-71 or ‘deficient’ in tumor mitochon- 
dria. Direct measurements of phospholipase activ- 
ities during Ca*+ transport are necessary to sub- 
stantiate this interpretation which is technically 
feasible with the recent development of sensitive 
and specific assay methods [18]. These studies 
suggest Mg*+ exerts different influences on Ca*+ 
transport, e.g., in liver, Mg*+ may prevent Ca2+ 
activation of mitochondrial phospholipase A2 or 
permeability effects of lysophosphatides [7,18] since 
nupercaine largely eliminates Mg*+ stimulation. 
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The Mg2+ (and perhaps ATP) stimulation of tumor 
mitochondrial Ca2+ uptake (table 2) presumably 
occurs by a different or additional mechanism, e.g., 
non-specific membrane stabilization at extremely 
high intramitochondrial Ca2+ levels (> 2 pequiv. 
Ca2+ /mg protein). 
The mechanism of ruthenium red-insensitive 
Ca2+ efflux from mitochondria is not known nor is 
that by which local anesthetics inhibit this Ca2+ 
release [9]. Nupercaine inhibited Ca2+ release from 
tumor mitochondria elicited with uncoupling agent 
(tig.lB) but not the steady state release under me- 
tabolizing conditions (fig. 1A). These may, there- 
fore, represent different pathways of Ca2+ efflux. 
Coupled respiration may ‘protect’ against changes 
in membrane structure (transitions) necessary for 
Ca2+ efflux [20] that are facilitated by uncoupling 
agents [21]. Calcium release by this pathway may 
not occur in the aerobic steady state. In experiments 
with rat liver mitochondria not presented, nuper- 
Caine inhibited Ca2+ egress by both pathways, i.e., 
on addition of ruthenium red during the aerobic 
steady state (cf. [9]) and Ca2+ release with ruth- 
enium red plus respiratory inhibitor (e.g., with anti- 
mycin, nupercaine inhibits by 70-20’3 as the Ca2+ 
load is increased from 200-800 nequiv. Ca2+/mg 
protein, contrary to results cited in [8] although for 
very different conditions). The sluggishness and 
nupercaine insensitivity of aerobic Ca2+ efflux 
from tumor mitochondria at large Ca2+ loads may 
be quite germane to their peculiar ability to take up 
and retain Ca2+ (e.g., release by ruthenium red 
occurred at 1 nequiv./min.mg for 400 nequiv. 
Ca2+/mg (tig.lA) compared to lO/min for rat 
liver; not shown). Steady state Ca2+ cycling via this 
pathway would be slow and therefore could cause 
minimal loss of internal Mg2+ and/or adenine 
nucleotides which is evidently crucial for maintain- 
ing the transmembrane electrical 
hence the driving force sustaining Ca 
potential [ 191, 
+ uptake. An 
interesting possibility is that phospholipase A2 ac- 
tivity is necessary for Ca2+ release via the nuper- 
Caine-sensitive efflux pathway operable during 
coupled electron flow. Therefore, this is not dem- 
onstrable in Ehrlich cell mitochondria as they are 
deficient in the enzyme. 
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